Evidence map›Paper›PMID 38774186›Full record

ArticleJCEM case reports2024

A Rare Case of Tumor-to-Tumor Metastasis: Renal Cell Carcinoma Metastasis to Papillary Thyroid Carcinoma.

Shourya Tadisina, Farhan Sami, Daniel Mettman, Maricel Ridella

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shourya TadisinaDivision of Endocrinology Diabetes and Metabolism, University of Missouri-Kansas City, Kansas City, MO 64108, USA.ORCID https://orcid.org/0009-0003-9612-0014
Farhan SamiDivision of Clinical Pathology, The University of Kansas, Kansas City, KS 66160, USA.
Daniel MettmanDepartment of Clinical Pathology, Division of Endocrinology Diabetes and Metabolism, Kansas City Veterans Association Medical Center, Kansas City, MO 64128, USA.
Maricel RidellaDepartment of Clinical Pathology, Division of Endocrinology Diabetes and Metabolism, Kansas City Veterans Association Medical Center, Kansas City, MO 64128, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy. Renal cell carcinoma (RCC) metastasis to the thyroid, albeit the most common carcinomatous metastasis to the thyroid, is rare, and tumor-to-tumor metastasis of RCC to PTC is even rarer. We present a case of a 65-year-old male with a history of RCC who presented with a thyroid nodule 7 years after left radical nephrectomy. Imaging showed the thyroid nodule predating the kidney tumor. Fine-needle aspiration biopsy was performed and showed 2 distinct cell populations, 1 of which was stained with RCC markers and another that was stained positively for thyroid markers. An interpretation of atypia of undetermined significance was rendered and molecular testing was indeterminate with ThyGeNEXT not detecting mutations and ThyraMIR positive for a level 2 microRNA pattern consistent with low risk for malignancy. The patient elected for active surveillance until follow-up thyroid ultrasound showed continued growth. At this point, a right hemithyroidectomy was performed. Pathology confirmed clear cell RCC metastasis to an infiltrative follicular variant papillary thyroid carcinoma. This case highlights the possibility of tumor-to-tumor metastasis in patients with a previous history of RCC even years after nephrectomy and in the absence of other metastatic lesions.

Indexed as

papillary thyroid carcinomarenal cell carcinomatumor-to-tumor metastasis

Identifiers

PMID38774186
PMCPMC11108084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.